No, they are expiring on Friday April 20th. In addition, there are 19,740, 21,945, 12,090, and 26,860 open interest in April $9, $10, $11, and $12 Option calls; respectively. These calls were sold at premium by MM and Hedge managers who shorted the stock and tried very hard to manipulated the stock and delay the DEA final scheduling by submitting negative biased comments to over while the DEA in order for these calls to expire worthless.. Also, some of these calls were sold as covered options by the long to collect premium while waiting.
Symbol Price Change Bid Ask Volume Open Interest
ARNA130420C00008000 0.28 Down 0.06 N/A N/A 212 25,849
Thank you for your clarification of Hoffman transaction. When I saw it last night , I got worried and I was thinking of selling some of ARNA's position. Thank Go I did not. I am long in ARNA since 2009. Last year I sold all my short term positions and kept some of my long term position for the DEA Schedule, Belviq launch, and the EMA approval. Since last June I have been holding these long term positions waiting!!! I did sell some shares when it pops and re-bought them back when PPS went below $8.0. I should have sold most of my position when PPS popped to $11.0 in January 2013 in anticipation of European approval. Also, I should have sold cover call options to get some profit while I am waiting.
Thanks Reza for a well written post. I agree with you and also with Jerry that "you should write article and exposed the BS the DEA is try to pull about the delayed because comments 44 of them do not need to be answered and the 22 are BS". The only reason these 22 negative comments were posted is to delay Belviq Launch by delaying the DEA schedule finalization.
Invest in high yield MPL stocks. I highly recommend CMLT. It is a well managed good quality, growth & income company. The have a good margin. Also, it is dividend growth company. In January they increase the dividend from $0.62 to $0.65 per share. I bought it in end of January at @ $32.5, got the quarterly dividend, sold it for @ $39 after good expansion news & the earning which exceeded analyst expectation. Currently, I am watching it for buying it back before the next Ex-Div. and earning dates.
How about CVS and Walgreen. How about Dr. OZ. special show about Bleviq, the New Novel safe FDA approved drug for weight loss! Last year or the year before, I saw Dr. OZ special show about Q as the " First FDA Approved Silver Bullet" drug for weight"!!!! Which we all knew it is not true.
Good logical post. Thanks. I made a very good options straddle strategy with Oct. $7.0 calls and $5.0 puts. As a result, If the results are good I will make a lot of money with my Oct. $7.0 call options. I bought enough puts to protect my investment If the results are bad. This way I can sleep at night going to any binary event.
Sentiment: Strong Buy
Not true. The truth is
THIS IS EXACTLY LIKE DNDN, HGSI, ARNA ALL OVER AGAIN Just to name a few AF wrote negative articles about them just few days before their Binary event: Phase III results, ADCOM, and FDA Approval. AND HE WAS WRONG!!! For More information read my post.
For the longs: Put him on the ignore list and do not reply.
Sentiment: Strong Buy
Just to name a few AF wrote negative articles about them just few days before their Binary event: Phase III results, ADCOM, and FDA Approval. AND HE WAS WRONG!!!
He is an idiot with a political science degree who knows nothing about science and bio tech. companies. He always bashes for Hedge Fund Managers
How convenient to be in option/put straddle but posting negative view article days prior to results. Huge short position, covering opportunity, and loading the boat with call options. It is typical of AF and Jim Creamer, ...etc.
Sentiment: Strong Buy
Here is Part II of Reza's comments on Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs
And then you compare Belviq to fenfluramine, failing to mention that
Qsymia has phen in it and then you put heart failure in the same
sentence which implicitly attributes it to Belviq which is exactly what
you want to make this a perfect disparaging piece. And you forgot to
mention that the FDA has determined Belviq doesn't have heart risks to
warrant a REMS program, and the receptor studies which I guess your
analyst is too dumb to understand.
You carry on lying: :"Belviq is indicated for people who have at least
one coexisting condition such as high blood pressure or Type 2 diabetes."
That's a flat out lie. A half truth is a lie. You forgot to mention it's also indicated for obese people without a comorbidity.
In quoting Belviq's efficacy, you forgot to mention Belviq's 11-12%
responder weight loss statistic because to use a totally meaningless 3%
number fits your apparent agenda to bash Arena better. Top experts in
this field know that that 3% number is just that -- meaningless, and the
responder numbers is what counts.
Shame on you Bloomberg. You just set a low in bad journalism. This is copied to your top management.
Here is Part 1 of Reza's comments on Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs
To: Ryan Flinn, Reg Gale, Andrew Berens
I often think, reading articles like your today#$%$ piece on Arena,
that some journalists are worse than prostitutes. Prostitutes still have
some honors but some journalists seem to be missing a very basic key to
journalism, which is truthfulness and integrity, and your piece today
proved me right again.
I wonder who funded this piece of journalistic disgrace? Who's behind these distortions and negligence?
"with a third of the population now considered overweight"
FALSE. two thirds of US population is overweight. You're lying.
“the drugs are not getting the uptake that people originally thought
they would,” Andrew Berens, an analyst with Bloomberg Industries,
This is why people call some analysts Anal-ysts. Is Andrew Berens paid
by the holders of the 58 million short interest in Arena, or is stupid,
or is ignorant? How can an analyst comment on a drug that he doesn't
even know if it's in the market yet or not? How can you assess a drug
that's not on the market yet to have had good uptake or not? This
statement needs to be corrected. This is a disparaging lie about Arena's
drug and market.
“The overall market has proven to have more hurdles than everyone expected.”
Based on what? Qsymia's launch alone? Why not admit that most of these
so called analysts were wrong about this entire space since last year
and they're still wrong. Qsymia is not Belviq Duh!!!!!!!! Totally
different mechanism of action. Totally different (and far better) safety
profile. Your Anal-yst didn't mention that or does he prefer not to
know it because whoever is paying him might not like it ??
And then you quote Cory Kasimov -- who's also been wrong about Arena so
far and will continue to be. There are no signs about Belviq's market
performance because it's not been in the market.
Another one-sided misinform article by Ryan Flinn. This article is #$%$. He is comparing the "Apples to Oranges"! He wrote: "New prescriptions of Vivus Inc.’s (VVUS) Qsymia, on the market since September, have declined 22 percent since peaking on Feb. 8, a drop that analysts say may be caused by high patient costs. That’s led shares of San Diego-based Arena Pharmaceuticals Inc. (ARNA) won’t climb when its drug, called Belviq, goes on sale in the U.S. later this year. " of San Diego-based Arena Pharmaceuticals Inc. (ARNA) won’t climb when its drug, called Belviq, goes on sale in the U.S. later this year. "
1. He can not compare Qsymia, a two generic cambo, to a new innovative drug Belviq.
2. VVUS launch was a failure because they try to do it alone with a small inexperience team of sale & marketing team.
3. ARNA Launch will be a success because they have Eisai doing it with a large experience sale and
Therefore, shares of San Diego-based Arena Pharmaceuticals Inc. (ARNA) will climb when its drug, called Belviq, goes on sale in the U.S. EARLY this year. Another intention mistake, he said later this year.
4. The price declined because of MM manipulation while waiting for the DEA final Schedule not because investors are betting that shares of ARNA won’t climb when it launches Belviq!!!
This guy should be reported to the SEC. Defenetly he is a basher working for the hedge fund managers who shorted ARNA and want cover.
Eisai is a big Japanese Pharmaceutical company. It is not manipulated by the MM like ARNA. Also, it is not affected that much by U.S. market nor the Cyprus Crisis!
I am sorry, I meant to say "Is it MM manipulation before the announcement of the results"? I know what bear raid is. It happened to other biotech stocks I owned before. Thank you Rick for the explanation.